Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis
1149
mi
from
Baltimore, MD
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis
1149
mi
from
Baltimore, MD
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative site
1444
mi
from
Boston, MA
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative site
1444
mi
from
Boston, MA
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
1440
mi
from
Brookline, MA
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
1440
mi
from
Brookline, MA
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
841
mi
from
Detroit, MI
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
841
mi
from
Detroit, MI
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
515
mi
from
Rochester, MN
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
515
mi
from
Rochester, MN
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
415
mi
from
St. Louis, MO
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
415
mi
from
St. Louis, MO
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
1286
mi
from
Teaneck, NJ
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
1286
mi
from
Teaneck, NJ
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
1060
mi
from
Buffalo, NY
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
1060
mi
from
Buffalo, NY
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis
1290
mi
from
New York, NY
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis
1290
mi
from
New York, NY
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis
1290
mi
from
New York, NY
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis
1290
mi
from
New York, NY
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
1122
mi
from
Rochester, NY
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
1122
mi
from
Rochester, NY
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
1333
mi
from
Stony Brook, NY
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
1333
mi
from
Stony Brook, NY
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
962
mi
from
Charlotte, NC
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
962
mi
from
Charlotte, NC
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
1048
mi
from
Durham, NC
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
1048
mi
from
Durham, NC
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
893
mi
from
Cleveland, OH
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
893
mi
from
Cleveland, OH
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
812
mi
from
Columbus, OH
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
812
mi
from
Columbus, OH
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis
974
mi
from
Pittsburgh, PA
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
777
mi
from
Knoxville, TN
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
777
mi
from
Knoxville, TN
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
615
mi
from
Nashville, TN
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
615
mi
from
Nashville, TN
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative site
353
mi
from
Dallas, TX
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative site
353
mi
from
Dallas, TX
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
572
mi
from
Houston, TX
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
572
mi
from
Houston, TX
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis
576
mi
from
San Antonio, TX
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis
576
mi
from
San Antonio, TX
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
1356
mi
from
Burlington, VT
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
1356
mi
from
Burlington, VT
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
1051
mi
from
Charlottesville, VA
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
1051
mi
from
Charlottesville, VA
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative Site
1412
mi
from
Seattle, WA
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative Site
1412
mi
from
Seattle, WA
Click here to add this to my saved trials
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/17/2014
Novartis Investigative site
573
mi
from
Madison, WI
FTY720 in Patients With Primary Progressive Multiple Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/17/2014
Novartis Investigative site
573
mi
from
Madison, WI
Click here to add this to my saved trials
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated:  1/17/2014
Clinical Research Facility
1290
mi
from
Lake Worth, FL
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated: 1/17/2014
Clinical Research Facility
1290
mi
from
Lake Worth, FL
Click here to add this to my saved trials
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated:  1/17/2014
Clinical Research Facility
806
mi
from
Fayetteville, GA
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated: 1/17/2014
Clinical Research Facility
806
mi
from
Fayetteville, GA
Click here to add this to my saved trials
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated:  1/17/2014
Clinical Research Facility
559
mi
from
Evansville, IN
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated: 1/17/2014
Clinical Research Facility
559
mi
from
Evansville, IN
Click here to add this to my saved trials
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated:  1/17/2014
Clinical Research Facility
1052
mi
from
Duncansville, PA
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated: 1/17/2014
Clinical Research Facility
1052
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated:  1/17/2014
Clinical Research Facility
327
mi
from
Allen, TX
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated: 1/17/2014
Clinical Research Facility
327
mi
from
Allen, TX
Click here to add this to my saved trials
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated:  1/17/2014
Clinical Research Facility
1124
mi
from
Arlington, VA
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Status: Enrolling
Updated: 1/17/2014
Clinical Research Facility
1124
mi
from
Arlington, VA
Click here to add this to my saved trials
International Ataxia Rating Scale in Younger Patients
APPLICABILITY OF THE INTERNATIONAL ATAXIA RATING SCALE (ICARS) IN YOUNGER PATIENTS AND DEVELOPMENT OF GLOBAL RATING INSTRUMENTS FOR PATIENTS WITH ATAXIA TELANGIECTASIA (AT)
Status: Enrolling
Updated:  1/17/2014
Carol Morsani USF Health Center
1117
mi
from
Tampa, FL
International Ataxia Rating Scale in Younger Patients
APPLICABILITY OF THE INTERNATIONAL ATAXIA RATING SCALE (ICARS) IN YOUNGER PATIENTS AND DEVELOPMENT OF GLOBAL RATING INSTRUMENTS FOR PATIENTS WITH ATAXIA TELANGIECTASIA (AT)
Status: Enrolling
Updated: 1/17/2014
Carol Morsani USF Health Center
1117
mi
from
Tampa, FL
Click here to add this to my saved trials
Enhancing Gluteus Maximus Recruitment
Enhancing Gluteus Maximus Recruitment: a Randomized Controlled Pilot Trial
Status: Enrolling
Updated:  1/21/2014
Mayo Clinic Rochester
515
mi
from
Rochester, MN
Enhancing Gluteus Maximus Recruitment
Enhancing Gluteus Maximus Recruitment: a Randomized Controlled Pilot Trial
Status: Enrolling
Updated: 1/21/2014
Mayo Clinic Rochester
515
mi
from
Rochester, MN
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Melmed Center
841
mi
from
Scottsdale, AZ
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Melmed Center
841
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Miller Children's Hospital
1171
mi
from
Long Beach, CA
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Miller Children's Hospital
1171
mi
from
Long Beach, CA
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
UC Davis MIND Institute
1281
mi
from
Sacramento, CA
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
UC Davis MIND Institute
1281
mi
from
Sacramento, CA
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Emory University
804
mi
from
Decatur, GA
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Emory University
804
mi
from
Decatur, GA
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Rush Medical Center
610
mi
from
Chicago, IL
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Rush Medical Center
610
mi
from
Chicago, IL
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Riley Hospital for Children
643
mi
from
Indianapolis, IN
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Riley Hospital for Children
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Children's Hospital - Boston
1441
mi
from
Boston, MA
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Children's Hospital - Boston
1441
mi
from
Boston, MA
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Lurie Center Massachusetts General Hospital
mi
from
Lexington, MA
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Lurie Center Massachusetts General Hospital
mi
from
Lexington, MA
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Mount Sinai School of Medicine/Seaver Center
mi
from
New York, NY
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Mount Sinai School of Medicine/Seaver Center
mi
from
New York, NY
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Institute for Behavioral Research on Staten Island
mi
from
Staten Island, NY
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Institute for Behavioral Research on Staten Island
mi
from
Staten Island, NY
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
University of North Carolina at Chapel Hill
1038
mi
from
Chapel Hill, NC
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
University of North Carolina at Chapel Hill
1038
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Nationwide Children's Hospital
811
mi
from
Columbus, OH
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  1/22/2014
Medical University of South Carolina
1063
mi
from
Charleston, SC
SynapDx Autism Gene Expression Analysis Study (STORY)
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 1/22/2014
Medical University of South Carolina
1063
mi
from
Charleston, SC
Click here to add this to my saved trials